Hospital Acquired Infection Treatment Market Size Report | Growth, Trends and Forecasts till 2030

Hospital Acquired Infection Treatment Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs, and Others), Infection Type (Urinary Tract Infections, Ventilator-Associated Pneumonia, Surgical Site Infections, Bloodstream Infections, and Other Hospital Infections), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)

  • Report Code : TIPRE00029976
  • Category : Pharmaceuticals
  • No. of Pages : 171
Buy Now

Hospital Acquired Infection Treatment Market Size Report | Growth, Trends and Forecasts till 2030

Buy Now

[Research Report] The hospital acquired infection treatment market is expected to grow from US$ 15,099.19 million in 2022 to US$ 19,978.39 million by 2030; it is anticipated to record a CAGR of 3.6% from 2022 to 2030.

Market Insights and Analyst View:

Hospital-acquired infections (HAIs), also known as nosocomially acquired infections, may develop in a variety of settings, including hospitals, long-term care institutions, and ambulatory settings, and they can also appear after discharge. HAIs can also involve occupational infections that affect healthcare workers. Key factors driving the hospital acquired infection treatment market growth are high prevalence of HAIs and growing focus on patient safety and quality care. However, the threat of antimicrobial resistance hinders hospital acquired infection treatment market growth.

Growth Drivers and Restraints: 

Central line-associated bloodstream infections, catheter-associated urinary tract infections, and ventilator-associated pneumonia are a few examples of healthcare-associated infections (HAIs). These infections, known as surgical site infections, can also arise at surgical sites. According to the Centers for Disease Control and Prevention (CDC) report “2020 National and State Healthcare-Associated Infections Progress Report" published in 2021, cases of central line-associated bloodstream infections, Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, and ventilator-associated events increased by 24%, 35%, and 15%, respectively, in the US between 2019 and 2020.

Furthermore, According to the January 2022 report from the National Healthcare Safety Network (NHSN), urinary tract infections (UTIs) are the fifth most common type of healthcare-associated infection. UTIs account for more than 9.5% of acute care hospital conditions. Catheter-Associated Urinary Tract Infection (CAUTI) is caused by urinary catheters used to drain urine from the bladder. CAUTI is one of the most frequent infections among hospitalized UTIs patients. According to the Centers for Disease Control and Prevention (CDC), nearly 75% of infections are related to a urinary catheter. During their hospital stays, 15% to 25% of hospitalized patients need to use urinary catheters. Prolonged urinary catheter use is the most major risk factor for getting CAUTI. CAUTI complications entail patient suffering, prolonged hospital stays, increased treatment costs, and even death.

Furthermore, according to the CDC, UTIs are responsible for more than 13,000 deaths each year. Acute uncomplicated cystitis causes around six days of discomfort, resulting in ∼7 million office visits every year at a cost of US$ 1.6 billion. As a result, rising number of HAI cases places a significant financial burden on the healthcare system. The increasing prevalence of CAUTI, combined with the increased demand for drugs for treatment, is propelling the market.

However, antimicrobial resistance poses a significant challenge to HAI treatment, limiting the efficacy of existing antimicrobial agents and necessitating the development of novel treatment strategies and antimicrobial alternatives to combat resistant pathogens effectively.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Hospital Acquired Infection Treatment Market: Strategic Insights

hospital-acquired-infection-treatment-market
Market Size Value inUS$ 15,099.19 million in 2022
Market Size Value byUS$ 19,978.39 million by 2030
Growth rateCAGR of 3.6% from 2022 to 2030
Forecast Period2022-2030
Base Year2022
Analyst Image

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

Report Segmentation and Scope:

The global hospital acquired infection treatment market is segmented on the basis of drug class, infection type, and distribution channel. Based on drug class, the hospital acquired infection treatment market is segmented into antibacterial drugs, antiviral drugs, antifungal drugs, and others. Based on infection type, the hospital acquired infection treatment is differentiated into urinary tract infections, ventilator-associated pneumonia, surgical site infections, bloodstream infections, and other hospital infections. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, e-commerce, and others. The hospital acquired infection treatment market, based on geography, is segmented into North America (the US, Canada, and Mexico), Europe (Germany, France, Italy, the UK, Russia, and the Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Segmental Analysis:

The hospital acquired infection treatment market, by drug class, is segmented into antibacterial drugs, antiviral drugs, antifungal drugs, and others. The antibacterial drugs segment held the largest market share in 2022 and is anticipated to register the highest CAGR during 2022–2030.

The hospital acquired infection treatment market, by infection type, is segmented into urinary tract infections, ventilator-associated pneumonia, surgical site infections, bloodstream infections, and other hospital infections. The urinary tract infections segment held the largest market share in 2022. However, the ventilator-associated pneumonia segment is anticipated to register the highest CAGR from 2022 to 2030.

The hospital acquired infection treatment market, by distribution channel, is segmented into hospital pharmacies, retail pharmacies, e-commerce, and others. In 2022, the hospital pharmacies segment held the largest market share, and the same segment is anticipated to register the highest CAGR during 2022–2030.

Regional Analysis:

Based on geography, the global hospital acquired infection treatment market is segmented into five key regions—North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

In 2022, North America held the largest share of the global hospital acquired infection treatment market size. The US has a high prevalence of HAI, which propels the hospital acquired infection treatment market growth. As per the CDC, on any given day, about 1 in 31 hospital patients has at least one HAI. Similarly, according to the Office of Disease Prevention and Health Promotion, HAIs and other infections can lead to sepsis, and it causes an ∼1.7 million illness cases and 270,000 deaths per year in the US. Thus, the high prevalence of HAI among people in the US fuels the hospital acquired infection treatment market growth.  

Industry Developments and Future Opportunities:

Various initiatives taken by key players operating in the global hospital acquired infection treatment market are listed below:

  1. In May 2023, Innoviva Specialty Therapeutics announced that the US Food and Drug Administration (FDA) had approved XACDURO (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use in patients aged 18 years and above for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter). Innoviva Specialty Therapeutics stated that it is focused on delivering innovative therapies in critical care and infectious diseases.
  2. In May 2023, Researchers of the Indian Institute of Science Education and Research (IISER), Pune and Central Drug Research Institute (CSIR-CDRI), Lucknow announced that they had discovered a potential new antibiotic against Acinetobacter baumannii, which frequently causes HAIs.
  3. In September 2020, Shionogi & Co Ltd announced that the FDA had approved a supplemental New Drug Application (sNDA) for FETROJA (cefiderocol) for the treatment of patients aged 18 years and above with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible Gram-negative microorganisms such as Enterobacter cloacae complex, Klebsiella pneumoniae, Acinetobacter baumannii complex, Escherichia coli, Pseudomonas aeruginosa, and Serratia marcescens.
  4. In June 2020, Merck announced that the US Food and Drug Administration (FDA) had approved a supplemental New Drug Application (sNDA) for RECARBRIO (imipenem, cilastatin, and relebactam) for the treatment of patients aged 18 years and above suffering from hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible Gram-negative microorganisms such as Acinetobacter calcoaceticus-baumannii complex, Klebsiella oxytoca, Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Klebsiella aerogenes, Pseudomonas aeruginosa, and Serratia marcescens.

Hospital Acquired Infection Treatment Market Report Scope

Competitive Landscape and Key Companies:

Merck & Co Inc, Pfizer Inc, AbbVie Inc, Paratek Pharmaceuticals Inc, Eugia US LLC, Abbott Laboratories, Cumberland Pharmaceuticals Inc, Innoviva Specialty Therapeutics Inc, Cipla Ltd, and Eli Lilly and Company are among the prominent players operating in the hospital acquired infection treatment market. These companies focus on new technologies, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide and increase their product range in specialty portfolios.

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Drug Class, Infection Type, Distribution Channel, and Geography

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is hospital acquired infection treatment?

Hospital-acquired infections (HAI), also known as nosocomially acquired infections. HAIs are infections acquired during medical treatment that were not present at the time of admission. They may develop in a variety of settings, including hospitals, long-term care institutions, and ambulatory settings, and they can also appear after discharge. HAIs can also involve occupational infections that affect healthcare workers.

Who are the major players in the hospital acquired infection treatment market?

The hospital acquired infection treatment market majorly consists of the players, including Merck & Co Inc, Pfizer Inc, AbbVie Inc, Paratek Pharmaceuticals Inc, Eugia US LLC, Abbott Laboratories, Cumberland Pharmaceuticals Inc, Innoviva Specialty Therapeutics Inc, Cipla Ltd, and Eli Lilly and Company.

What factors drive the hospital acquired infection treatment market?

Key factors driving the hospital acquired infection treatment market growth include the high prevalence of hospital-acquired infections (HAI) and the growing focus on patient safety and quality care.

What was the estimated hospital acquired infection treatment market size in 2022?

The hospital acquired infection treatment market was valued at US$ 15,099.19 million in 2022.

Which distribution channel segment dominates the hospital acquired infection treatment market?

The hospital acquired infection treatment market, by distribution channel, is segmented into hospital pharmacies, retail pharmacies, e-commerce, and others. In 2022, the hospitals pharmacies segment held the largest market share, and the same segment is anticipated to register the highest CAGR during 2022–2030.

What are the growth estimates for the hospital acquired infection treatment market till 2030?

The hospital acquired infection treatment market is expected to be valued at US$ 19,978.39 million in 2030.

Which infection type segment dominates the hospital acquired infection treatment market?

The hospital acquired infection treatment market, by infection type, is segmented into urinary tract infections, ventilator-associated pneumonia, surgical site infections, bloodstream infections, and other hospital infections. The urinary tract infections segment held a larger market share in 2022; However, the ventilator-associated pneumonia segment is anticipated to register a higher CAGR during 2022-2030.

Which drug class segment dominates the hospital acquired infection treatment market?

The hospital acquired infection treatment market, by drug class, is segmented into antibacterial drugs, antiviral drugs, antifungal drugs, and others. The antibacterial drugs segment held a larger market share in 2022, and the same segment is anticipated to register a higher CAGR during 2022-2030.

1. Introduction

1.1 Scope of the Study

1.2 Market Definition, Assumptions and Limitations

1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights

2.2 Market Attractiveness Analysis

3. Research Methodology

4. Hospital Acquired Infection Treatment Market Landscape

4.1 Overview

4.2 PEST Analysis

5. Hospital Acquired Infection Treatment Market - Key Market Dynamics

5.1 Key Market Drivers

5.2 Key Market Restraints

5.3 Key Market Opportunities

5.4 Future Trends

5.5 Impact Analysis of Drivers and Restraints

6. Hospital Acquired Infection Treatment Market - Global Market Analysis

6.1 Hospital Acquired Infection Treatment - Global Market Overview

6.2 Hospital Acquired Infection Treatment - Global Market and Forecast to 2030

7. Hospital Acquired Infection Treatment Market – Revenue Analysis (USD Million) – By Drug Class, 2020-2030

7.1 Overview

7.2 Antibacterial Drugs

7.3 Antiviral Drugs

7.4 Antifungal Drugs

7.5 Others

8. Hospital Acquired Infection Treatment Market – Revenue Analysis (USD Million) – By Infection Type, 2020-2030

8.1 Overview

8.2 Urinary Tract Infections

8.3 Ventilator-associated Pneumonia

8.4 Surgical Site Infections

8.5 Bloodstream Infections

8.6 Other Hospital Infections

9. Hospital Acquired Infection Treatment Market – Revenue Analysis (USD Million) – By Distribution Channel, 2020-2030

9.1 Overview

9.2 Hospital Pharmacies

9.3 Retail Pharmacies

9.4 E-Commerce

9.5 Others

10. Hospital Acquired Infection Treatment Market - Revenue Analysis (USD Million), 2020-2030 – Geographical Analysis

10.1 North America

10.1.1 North America Hospital Acquired Infection Treatment Market Overview

10.1.2 North America Hospital Acquired Infection Treatment Market Revenue and Forecasts to 2030

10.1.3 North America Hospital Acquired Infection Treatment Market Revenue and Forecasts and Analysis - By Drug Class

10.1.4 North America Hospital Acquired Infection Treatment Market Revenue and Forecasts and Analysis - By Infection Type

10.1.5 North America Hospital Acquired Infection Treatment Market Revenue and Forecasts and Analysis - By Distribution Channel

10.1.6 North America Hospital Acquired Infection Treatment Market Revenue and Forecasts and Analysis - By Countries

10.1.6.1 United States Hospital Acquired Infection Treatment Market

10.1.6.1.1 United States Hospital Acquired Infection Treatment Market, by Drug Class

10.1.6.1.2 United States Hospital Acquired Infection Treatment Market, by Infection Type

10.1.6.1.3 United States Hospital Acquired Infection Treatment Market, by Distribution Channel

10.1.6.2 Canada Hospital Acquired Infection Treatment Market

10.1.6.2.1 Canada Hospital Acquired Infection Treatment Market, by Drug Class

10.1.6.2.2 Canada Hospital Acquired Infection Treatment Market, by Infection Type

10.1.6.2.3 Canada Hospital Acquired Infection Treatment Market, by Distribution Channel

10.1.6.3 Mexico Hospital Acquired Infection Treatment Market

10.1.6.3.1 Mexico Hospital Acquired Infection Treatment Market, by Drug Class

10.1.6.3.2 Mexico Hospital Acquired Infection Treatment Market, by Infection Type

10.1.6.3.3 Mexico Hospital Acquired Infection Treatment Market, by Distribution Channel

Note - Similar analysis would be provided for below mentioned regions/countries

10.2 Europe

10.2.1 Germany

10.2.2 France

10.2.3 Italy

10.2.4 Spain

10.2.5 United Kingdom

10.2.6 Rest of Europe

10.3 Asia-Pacific

10.3.1 Australia

10.3.2 China

10.3.3 India

10.3.4 Japan

10.3.5 South Korea

10.3.6 Rest of Asia-Pacific

10.4 Middle East and Africa

10.4.1 South Africa

10.4.2 Saudi Arabia

10.4.3 U.A.E

10.4.4 Rest of Middle East and Africa

10.5 South and Central America

10.5.1 Brazil

10.5.2 Argentina

10.5.3 Rest of South and Central America

11. Industry Landscape

11.1 Mergers and Acquisitions

11.2 Agreements, Collaborations, Joint Ventures

11.3 New Product Launches

11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

12.1 Heat Map Analysis by Key Players

12.2 Company Positioning and Concentration

13. Hospital Acquired Infection Treatment Market - Key Company Profiles

13.1 Merck and Co. Inc.

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

Note - Similar information would be provided for below list of companies

13.2 Pfizer Inc

13.3 AbbVie Inc

13.4 Paratek Pharmaceutical Inc

13.5 Eugia US LLC

13.6 Abbott Laboratories

13.7 Cumberland Pharmaceuticals Inc

13.8 Innoviva Specialty Therapeutics Inc

13.9 Cipla Ltd

13.10 Eli Lilly and Company

14. Appendix

14.1 Glossary

14.2 About The Insight Partners

14.3 Market Intelligence Cloud

The List of Companies - Hospital Acquired Infection Treatment Market

  1. Merck & Co Inc
  2. Pfizer Inc
  3. AbbVie Inc
  4. Paratek Pharmaceuticals Inc
  5. Eugia US LLC
  6. Abbott Laboratories
  7. Cumberland Pharmaceuticals Inc
  8. Innoviva Specialty Therapeutics Inc
  9. Cipla Ltd
  10. Eli Lilly and Company

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Pharmaceuticals : READ MORE..